Karin Jordan

Summary

Affiliation: Martin Luther University
Country: Germany

Publications

  1. ncbi [Chemotherapy induced-vomiting--a practical guide for prevention and therapy]
    K Jordan
    Klinik für Innere Medizin IV, Hämatologie Onkologie, Martin Luther Universitat Halle Wittenberg, Ernst Grube Strasse 40, 06120 Halle Salle
    Dtsch Med Wochenschr 131:1869-72. 2006
  2. ncbi A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
    K Jordan
    Department for Hematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle, Germany
    Support Care Cancer 15:1023-33. 2007
  3. ncbi Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations
    Karin Jordan
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Oncologist 12:1143-50. 2007
  4. ncbi Comparative activity of antiemetic drugs
    Karin Jordan
    Department of Internal Medicine IV, Haematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Crit Rev Oncol Hematol 61:162-75. 2007
  5. doi The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination
    K Jordan
    Department of Internal Medicine IV Oncology Hematology, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Bone Marrow Transplant 46:784-9. 2011
  6. doi Venous access ports: frequency and management of complications in oncology patients
    Karin Jordan
    Department of Oncology Haematology, University Hospital of the Martin Luther University Halle Wittenberg, Germany
    Onkologie 31:404-10. 2008
  7. doi Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy
    Karin Jordan
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle, Saale, Germany
    Eur J Cancer 45:1184-7. 2009
  8. doi [New antiemetic strategies - not only in oncology]
    K Jordan
    Klinik für Innere Medizin IV, Universitätsklinikum Halle, Ernst Grube Strasse 40, 06120, Halle, Deutschland
    Internist (Berl) 50:887-94. 2009
  9. doi Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009
    Karin Jordan
    Department of Medical Oncology and Hematology, University of Halle, Ernst Grube Strasse 40, Halle, Germany
    Support Care Cancer 19:S37-42. 2011
  10. doi Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting
    K Jordan
    Department of Oncology Hematology, University of Halle, Halle, Germany
    Eur J Cancer Care (Engl) 19:603-9. 2010

Detail Information

Publications26

  1. ncbi [Chemotherapy induced-vomiting--a practical guide for prevention and therapy]
    K Jordan
    Klinik für Innere Medizin IV, Hämatologie Onkologie, Martin Luther Universitat Halle Wittenberg, Ernst Grube Strasse 40, 06120 Halle Salle
    Dtsch Med Wochenschr 131:1869-72. 2006
    ..Here, the most recent developments in the antiemetic therapy including the latest guidelines for antiemetic prophylaxis are described...
  2. ncbi A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
    K Jordan
    Department for Hematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle, Germany
    Support Care Cancer 15:1023-33. 2007
    ..Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV)...
  3. ncbi Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations
    Karin Jordan
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Oncologist 12:1143-50. 2007
    ..This review focuses, in particular, on the conformity and differences of these three guidelines. Furthermore, open questions and trends in the field of antiemesis are discussed as well...
  4. ncbi Comparative activity of antiemetic drugs
    Karin Jordan
    Department of Internal Medicine IV, Haematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Crit Rev Oncol Hematol 61:162-75. 2007
    ..Here, the most recent developments in the antiemetic therapy, including new antiemetic drugs and the latest guidelines for antiemetic prophylaxis, are reviewed...
  5. doi The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination
    K Jordan
    Department of Internal Medicine IV Oncology Hematology, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Bone Marrow Transplant 46:784-9. 2011
    ....
  6. doi Venous access ports: frequency and management of complications in oncology patients
    Karin Jordan
    Department of Oncology Haematology, University Hospital of the Martin Luther University Halle Wittenberg, Germany
    Onkologie 31:404-10. 2008
    ..This review will give a broad overview on the frequency and possible complications related to port devices. Furthermore, this review suggests strategies for management including proposals to avoid such complications...
  7. doi Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy
    Karin Jordan
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle, Saale, Germany
    Eur J Cancer 45:1184-7. 2009
    ..In multiple-day chemotherapy (MDC), the combination of a 5-HT(3)-antagonist plus dexamethasone is still a standard of care. The role of a NK-1-antagonist remains to be defined...
  8. doi [New antiemetic strategies - not only in oncology]
    K Jordan
    Klinik für Innere Medizin IV, Universitätsklinikum Halle, Ernst Grube Strasse 40, 06120, Halle, Deutschland
    Internist (Berl) 50:887-94. 2009
    ..However, other conventional antiemetic drugs are still in use and should not be underestimated...
  9. doi Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009
    Karin Jordan
    Department of Medical Oncology and Hematology, University of Halle, Ernst Grube Strasse 40, Halle, Germany
    Support Care Cancer 19:S37-42. 2011
    ....
  10. doi Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting
    K Jordan
    Department of Oncology Hematology, University of Halle, Halle, Germany
    Eur J Cancer Care (Engl) 19:603-9. 2010
    ..Thus, in addition to other established risk factors for PCNV, patients should be screened for these QoL factors in order to improve the control of PCNV and facilitate the selection of appropriate, individualised anti-emetic prophylaxes...
  11. doi Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study
    K Jordan
    Department of Internal Medicine IV, Oncology Hematology, Martin Luther University of Halle, Ernst Grube Strasse 40, Halle Wittenberg, Germany
    Bone Marrow Transplant 45:1704-9. 2010
    ..The efficacy in these heavily pretreated patients including possible reversal of chemotherapy resistance by the addition of bevacizumab indicates a possible potential of bevacizumab in this combination...
  12. ncbi [Extravasation of chemotherapeutic agents: prevention and therapy]
    K Jordan
    Klinik für Innere Medizin IV, Hämatologie Onkologie Martin Luther Universität Halle Wittenberg, Halle
    Dtsch Med Wochenschr 130:33-7. 2005
    ..In addition to these guidelines an extravasation kit including all necessary materials and drugs to treat extravasations should be available...
  13. ncbi Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting
    Karin Jordan
    Department of Internal Medicine IV, Hematology Oncology, Martin Luther University Halle Wittenberg, Germany
    Onkologie 28:88-92. 2005
    ..To assess the antiemetic efficacy of an oral suspension of granisetron/dexamethasone in patients receiving chemotherapy and to determine whether quality-of-life parameters influence the risk for postchemotherapy nausea and vomiting (PCNV)...
  14. ncbi Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis
    Karin Jordan
    Department for Hematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120, Halle, Germany
    Support Care Cancer 13:26-31. 2005
    ....
  15. ncbi Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy
    Karin Jordan
    Internal Medicine IV, Hematology Oncology, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Eur J Haematol 74:263-6. 2005
    ..Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab...
  16. ncbi Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy
    Karin Jordan
    Department of Hematology Oncology, Martin Luther University Halle Wittenberg, Germany
    Onkologie 29:39-43. 2006
    ..Therefore, the combination of a 5-HT(3) receptor antagonist, dexamethasone and aprepitant should be considered as a new standard antiemetic therapy...
  17. doi Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial
    Patrick Jahn
    Institute for Health and Nursing Science, Medical Faculty, Martin Luther University Halle Wittenberg, Magdeburger Strasse 8, 06097, Halle, Germany
    Support Care Cancer 17:1543-52. 2009
    ..The purpose of this present study was to evaluate Self-care Improvement through Oncology Nursing (SCION) program to reduce distressing anorexia, nausea, and emesis (ANE) in cancer patients undergoing chemotherapy...
  18. ncbi Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment
    Karin Jordan
    Department of Internal Medicine IV, Haematology Oncology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Eur J Cancer 41:199-205. 2005
    ..Due to these new developments, revised antiemetic guidelines have been set. Here, the most recent developments in antiemetic therapy, including these guidelines, are reviewed...
  19. doi Port catheter insufficiency: incidence and clinical-radiological correlations
    Alexey Surov
    Dept of Radiology, University Hospital of the Martin Luther University Halle Wittenberg, Germany
    Onkologie 31:455-61. 2008
    ..The purpose of this study was to analyse the radiological findings and corresponding clinical signs in patients with port catheter insufficiency...
  20. ncbi Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment
    H J Schmoll
    Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Ann Oncol 17:1000-6. 2006
    ..We compared an aprepitant regimen with a control regimen of ondansetron + dexamethasone given for 4 days...
  21. ncbi Atypical pulmonary embolism of port catheter fragments in oncology patients
    Alexey Surov
    Department of Radiology, Martin Luther University Halle Wittenberg, Halle Saale, Germany
    Support Care Cancer 14:479-83. 2006
    ..Embolization of venous catheter fragments to the pulmonary vasculature is a very rare form of pulmonary embolism which is only sporadically reported in the literature. The incidence and clinical picture of this complication are unknown...
  22. pmc Promising cytotoxic activity profile of fermented wheat germ extract (Avemar®) in human cancer cell lines
    Thomas Mueller
    University of Halle, Department Internal Medicine, Oncology Hematology and Hemostaseology, Ernst Grube Str, 40, 06120 Halle Saale, Germany
    J Exp Clin Cancer Res 30:42. 2011
    ..Further evaluation of FWGE as a candidate for clinical combination drug regimens appeared to be warranted...
  23. ncbi Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers
    Karin Jordan
    Department of Hematology and Oncology, University of Halle, Germany
    Clin Colorectal Cancer 4:46-50. 2004
    ..This trial served as basis for a randomized multicenter phase II study comparing capecitabine/oxaliplatin and capecitabine/irinotecan as first-line therapy in patients with advanced colorectal cancer...
  24. pmc Anthracycline extravasation injuries: management with dexrazoxane
    Karin Jordan
    Clinic for Internal Medicine IV, Department for Oncology and Haematology, University Hospital Halle, Halle, Germany
    Ther Clin Risk Manag 5:361-6. 2009
    ..In two multicenter studies dexrazoxane has proven to be highly effective in preventing skin necrosis and ulceration. This review focuses on the development and management of dexrazoxane in anthracycline extravasation injuries...
  25. ncbi Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab
    Berit Hain
    Department of Neurology, Martin Luther University of Halle Wittenberg, Ernst Grube Strasse 40, 06120 Halle Saale, Germany
    Muscle Nerve 33:575-80. 2006
    ..The patient continued to remain stable 12 months after initiation of therapy. This case report demonstrates that rituximab may be an effective and tolerable treatment in MuSK antibody-positive myasthenia gravis...
  26. pmc Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
    Alexander Stein
    Department of Internal Medicine IV, Oncology Hematology Hemostaseology, Martin Luther University Halle Wittenberg, Ernst Grube Str 40, 06120 Halle Saale, Germany
    Ther Adv Med Oncol 2:51-63. 2010
    ..Current research focuses on establishing predictive factors for CID like uridine diphosphate glucuronosyltransferase-1A1 polymorphisms for irinotecan or dihydropyrimidine-dehydrogenase insufficiency for fluoropyrimidines...